Analyst Consensus ?
ConsensusHold23 ratings
Bullish1356.5%
Neutral939.1%
Bearish14.4%
IDEXX Laboratories, Inc. · IDXX · FY2025 Q1 · Calendar Q2 2025
IDEXX raises 2025 outlook as new diagnostics gain traction
The supplied analysis supports a constructive operating thesis for IDEXX: resilient demand, pricing, consumables, software, and new diagnostic platforms supported growth and a higher outlook. The evidence is balanced by unresolved sensitivity to clinic visits, tariffs, foreign exchange, and execution on instrument placements.
Reported Before market openNASDAQHealthcare
$41.33B market cap
70quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $2.93
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $996.2M
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+9.0%
Event window
SPY move
+0.7%
Same window
Abnormal move
+8.2%
Stock minus SPY
Volume
1.2×
Versus trailing sessions
Subsequent drift
+8.9%
Up to 20 sessions
IDXXSPY benchmark
Ask FN2 about IDXX FY2025 Q1
Transcript, numbers and history already loaded
What drove IDXX's +9.0% move after FY2025 Q1 earnings?What changed in IDXX's guidance and outlook in FY2025 Q1?Give me the bull and bear case for IDXX after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management described early adoption of Cancer Dx and inVue Dx, raised full-year revenue and EPS guidance, and lifted the operating-margin outlook. InVue Dx moved from controlled rollout to full volume, while the company continued to flag clinic-visit headwinds, tariff exposure, and FX risk.
Guidance delta
Management raised full-year 2025 revenue guidance to $4.095–$4.210 billion and EPS guidance to $11.93–$12.43, while targeting 4,500+ instrument placements.
Key takeaways
- Q1 organic revenue growth was 5%, supported by companion-animal diagnostics, water, and LPD.
- Cancer Dx received more than 1,000 practice orders in its first month, while inVue Dx reached about 900 installations by April.
- Management cited 62.4% gross margin and raised the full-year operating-margin outlook to 31.1%–31.6%.
- Clinic-visit headwinds remain, but pricing, consumables, software, and new-platform adoption were resilient.
- The main watchpoints are placement pace, visit recovery, tariffs, and foreign exchange.
Management priorities
- Scale Cancer Dx and inVue Dx adoption.
- Reach 4,500+ instrument placements in 2025.
- Expand the oncology menu and add five-needle FNA capability to inVue Dx.
- Continue software-platform integration and R&D investment.
Follow IDXX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$520.31Current
$247Low
$637.65Average
$830High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 14, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Overweight | Overweight | Maintain | Aug 11, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Stifel | Buy | Buy | Maintain | Mar 31, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Feb 9, 2026 |
| BTIG | Buy | Buy | Maintain | Feb 3, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Nov 4, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Nov 4, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Jul 17, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Apr 21, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 17, 2024 |
| Atlantic Equities | Neutral | Overweight | Downgrade | Aug 2, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 13, 2021 |
| Guggenheim | Neutral | Buy | Downgrade | Jul 12, 2021 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 22, 2019 |
| Canaccord Genuity | Buy | Buy | Maintain | May 2, 2019 |
| Bank of America | Buy | Buy | Maintain | Nov 2, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | Jan 16, 2018 |
| Aegis Capital | Sell | Sell | Maintain | Jun 1, 2017 |
| CL King | Neutral | Neutral | Maintain | Apr 1, 2016 |
| Raymond James | Market Perform | Outperform | Downgrade | Aug 28, 2015 |
| Feltl & Co. | Hold | Sell | Upgrade | Jul 23, 2015 |
| Bank oferica | Buy | Buy | Maintain | Apr 20, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $520.31. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Glen Santangelo | $710 | $595.76 | +36.5% | Aug 11, 2026 |
| UBS | Analyst unavailable | $620 | $559.86 | +19.2% | Jul 27, 2026 |
| UBS | Andrea Alfonso | $640 | $569.17 | +23.0% | Apr 28, 2026 |
| Piper Sandler | Analyst unavailable | $750 | $644.61 | +44.1% | Feb 9, 2026 |
| Barclays | Glen Santangelo | $800 | $642.94 | +53.8% | Feb 5, 2026 |
| UBS | Andrea Alfonso | $730 | $639.6 | +40.3% | Feb 3, 2026 |
| BTIG | Analyst unavailable | $800 | $639.6 | +53.8% | Feb 3, 2026 |
| Barclays | Glen Santangelo | $850 | $706.65 | +63.4% | Dec 8, 2025 |
| Morgan Stanley | Analyst unavailable | $805 | $721.04 | +54.7% | Nov 4, 2025 |
| UBS | Analyst unavailable | $750 | $722.94 | +44.1% | Nov 4, 2025 |
| BTIG | Analyst unavailable | $830 | $722.94 | +59.5% | Nov 4, 2025 |
| Jefferies | Keith Devas | $830 | $722.94 | +59.5% | Nov 4, 2025 |
| Leerink Partners | Analyst unavailable | $785 | $722.94 | +50.9% | Nov 3, 2025 |
| Stifel Nicolaus | Jonathan Block | $775 | $722.94 | +48.9% | Nov 3, 2025 |
| Stifel Nicolaus | Jonathan Block | $700 | $628.54 | +34.5% | Oct 31, 2025 |
| UBS | Andrea Alfonso | $720 | $638.89 | +38.4% | Oct 1, 2025 |
| Morgan Stanley | Analyst unavailable | $722 | $641.94 | +38.8% | Aug 5, 2025 |
| BTIG | Analyst unavailable | $785 | $641.94 | +50.9% | Aug 5, 2025 |
| Stifel Nicolaus | Analyst unavailable | $640 | $682.78 | +23.0% | Aug 4, 2025 |
| Stifel Nicolaus | Jonathan Block | $510 | $495.73 | -2.0% | Jun 24, 2024 |
| Barclays | Analyst unavailable | $590 | $507.68 | +13.4% | Feb 8, 2023 |
| J.P. Morgan | Analyst unavailable | $550 | $487.04 | +5.7% | Feb 7, 2023 |
| Atlantic Equities | Analyst unavailable | $600 | $485.53 | +15.3% | Feb 7, 2023 |
| Oppenheimer | Analyst unavailable | $247 | $483.2 | -52.5% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $268 | $483.2 | -48.5% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $273 | $420.63 | -47.5% | Dec 9, 2022 |
| Morgan Stanley | Analyst unavailable | $543 | $435.78 | +4.4% | Nov 15, 2022 |
| Stifel Nicolaus | Analyst unavailable | $500 | $355.62 | -3.9% | Jun 24, 2022 |
| Goldman Sachs | Analyst unavailable | $530 | $357.33 | +1.9% | May 19, 2022 |
| Barclays | Balaji Prasad | $700 | $364.5 | +34.5% | May 6, 2022 |
Track every rating change on IDXX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationIDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services.…
Historical context
All IDXX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| UNH UnitedHealth Group Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | +0.5% | UnitedHealth raises 2026 EPS outlook as AI and care initiatives advance |
| JNJ Johnson & Johnson | FY2026 Q3 · Calendar Q4 2026 | — | -5.2% | J&J raises 2026 outlook as oncology growth offsets softer MedTech |
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
Latest beats and misses
Who reports nextBeat on EPS
Get the IDXX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-17T00:02:52.217204+00:00
- Polygon adjusted daily market bars · 2026-10-13T23:40:44.408131+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-13T23:40:44.405336+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-13. For educational purposes only; not investment advice.